NobleCon 18. Gerri Henwood, President and Chief Executive Officer, presented at the conference. The presentation highlighted continued ANJESO growth, reduced cash burn and pipeline progress of the Company’s Neuromuscular Blockers (NMBs) and NMB Reversal Agents. A replay of the presentation can be found Here .ANJESO is growing. Growth has been strong as Baudax Bio continues to win formularies, not only in regional hospitals and ambulatory surgery centers (ASCs), but also integrated delivery networks (IDNs) and national ASC groups. Highly positive clinical experience has helped account penetration.Lowered expenses. The recently enacted headcount and expense reductions will substantially curtail cash burn, providing a longer pathway to advance ANJESO and the NMBs. The Company is focused on key accounts and contracts but is also evaluating possible partnering opportunities for ANJESO.Watch out for NMBs. The NMB pipeline represents a very large opportunity. Although the Company is reducing expenses, they are leaving room to advance their intermediate acting and ultra-short acting agents, as well as their novel reversal agent. BX1000 (intermediate) Phase II could have results by end of 2022, BX2000 (ultra-short) could have dose escalation results early 2023, and the reversal agent could enter clinical phase early 2023.Maintain Outperform and $10 price target. Continued progress for ANJESO and lowered cash burn is expected to produce quicker profitability. Our target is based on 2025 EPS of $1.12, discounted 30% and applying a 20x multiple. Read More >>